Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Ibuprofen"

36 News Found

Alkem launches Ibuprofen and Famotidine tablets in US
News | August 07, 2021

Alkem launches Ibuprofen and Famotidine tablets in US

Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg


IOLCP revenue rises 11.5% YoY to Rs. 2,319.1 crore in FY26
News | May 21, 2026

IOLCP revenue rises 11.5% YoY to Rs. 2,319.1 crore in FY26

Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore


Solara announces closure of US FDA inspection at Puducherry facility
Drug Approval | April 30, 2026

Solara announces closure of US FDA inspection at Puducherry facility

The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets


IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
News | February 13, 2026

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY


Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader
Opinion | January 07, 2026

Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader

India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry


FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy
News | September 24, 2025

FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy

Agency initiates safety label change and notifies physicians of possible link


Briefs: Emcure and Relonchem
Drug Approval | February 27, 2025

Briefs: Emcure and Relonchem

USFDA inspection at Emcure Pharmaceuticals API facility


SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
News | August 06, 2024

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024


IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
News | February 07, 2024

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM


SMS Pharmaceuticals reports robust Q2FY24 operational performance
News | November 10, 2023

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore